Concepedia

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial

Dian Zhou, Qian Sun, Jieyun Xia, Weiying Gu, Jun Qian, Wanchuan Zhuang, Zhiling Yan, Hai Cheng, Wei Chen, Feng Zhu,

The Lancet Haematology · 2024 · 50 citations · 27 references

DOI

Concepts

References

27

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

S. Vincent Rajkumar, Meletios Α. Dimopoulos, Antonio Palumbo et al. · The Lancet Oncology · 2014 · 4.9K citations · Full text

, , +11

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · New England Journal of Medicine · 2021 · 2.4K citations · Full text

, , +17

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje, Jesús G. Berdeja, Yi Lin et al. · New England Journal of Medicine · 2019 · 1.7K citations · Full text

, , +17

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.7K citations

, , +17

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Jacques J. M. van Dongen, Ludovic Lhermitte, Sebastian Böttcher et al. · Leukemia · 2012 · 915 citations · Full text

, , +15